BioStem Technologies (BSEM) Q3 2026 earnings review
BioStem lifts its sales floor, but cash hits $1 million
BioStem Technologies, a maker of surgical and wound grafts from placental tissue, is running out of cash while its hospital sales plateau. Third-quarter revenue slipped 3% from the second quarter to $7.6 million as doctor-office sales shrank and hospital sales per day barely moved by our math. Gross margin dropped five percentage points after initial supply discounts expired, and cash fell to $1 million even after a $3 million stock sale. Chair and chief executive Jason Matuszewski raised the bottom of the full-year sales outlook, but by our math the plan points to lower sales in the fourth quarter.
| Hospital revenue | $6.8M +1.5% from last quarter (+0.2% per day by our math) |
|---|---|
| Gross margin | 56.2% 61.3% last quarter |
| Cash on hand | $1.0M $7.0M last quarter ($10M bill still unpaid) |
| Full-year revenue outlook | Raised $1M middle of the range: $28.5M (prior $27.5M) |
⚖️ Verdict: 🔴 Bearish
The story got worse because BioStem missed its September deadline to pay a $10 million bill to supplier BioTissue and burned $8.8 million of operating cash in the quarter. The company is negotiating to restructure that unpaid bill and plans to cut $10 million to $12 million in yearly cash costs starting next year. On the positive side, more hospital customers bought multiple product lines, and third-quarter sales beat what the cautious prior outlook implied.
The question now is whether BioStem can defer the $10 million BioTissue payment and fund operations until its equity line opens in April 2027 and in-house manufacturing begins. Either BioTissue grants payment relief while the planned cost cuts close the cash deficit, or the company faces a distressed financing or restructuring. The third-quarter 10-Q filing and first-quarter 2027 cash burn will settle it.
🐂 Bull Case
Customers Are Buying More Product Lines
BioStem sells placental tissue grafts used by doctors to heal surgical and chronic wounds. Since buying the Neox and Clarix hospital brands from BioTissue in January, the company has worked to sell its older Vendaje wound grafts alongside the new hospital lines.
- Customers buying two or more product lines: up 14% from the second quarter
- Customers buying three or more product lines: up more than 40% from the second quarter
- Customers ordering in back-to-back quarters: up 6% from the second quarter
The medical tissue group also took over billing and logistics from BioTissue in August, added Vendaje to its two largest hospital purchasing contracts in September, and plans to present venous leg ulcer trial results in December. This commercial progress shows hospitals accept the combined catalog.
What to watch: hospital revenue in the fourth quarter. If cross-selling and the new purchasing contracts are working, total hospital dollars must start rising faster than the calendar.
BioStem Lifted the Floor on Its Outlook
Three months ago, management set a full-year revenue forecast of $26 million to $29 million. Because first-half sales were already $14.0 million, that plan implied an average of $6.0 million to $7.5 million per quarter in the second half by our math.
Third-quarter revenue reached $7.6 million, beating that implied pace even though total sales dipped 3.3% from the second quarter. That beat allowed BioStem to raise the bottom of its full-year target by $2 million, to a new range of $28 million to $29 million. Beating the implied third-quarter bar proves the earlier forecast had a cushion, but it does not mean the business is accelerating.
What to watch: fourth-quarter revenue against the $6.8 million implied by the middle of the new full-year outlook. Matching Q3's $7.6 million would put full-year revenue above the top of the range.
🐻 Bear Case
Cash Hit $1 Million With $10 Million Unpaid
BioStem owes $10.0 million to BioTissue for the regulatory clearance of an injectable wound product, a bill that had an extended deadline of September 15. Chair and chief executive Jason Matuszewski said the company is focused on "strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven."
The company did not pay the $10.0 million bill in the third quarter. Instead, BioStem recorded $1.0 million in payment extension costs and said it is working with BioTissue "to restructure the terms of the $10.0 million Clearance Payment in order to lower near-term cash obligations".
- Cash on hand on September 30: $1.0 million, down from $7.0 million in June
- Cash used in operations in Q3: $8.8 million, up from $5.5 million in Q2
- New cash raised: $3.0 million from a September stock sale, plus $1.0 million from executive option exercises after quarter-end
Even with the $3.0 million stock sale on the last day of the quarter, cash fell to $1.0 million and the $10.0 million bill "remains unpaid". A new $40 million equity line with Roth Principal Investments cannot be used until April 2027 unless Roth waives the restriction, so BioStem remains in an acute cash squeeze.
What to watch: the restructuring terms with BioTissue in the third-quarter 10-Q filing. A failure to defer the $10.0 million payment would force an immediate financing or default.
Hospital Sales Per Day Barely Moved
"We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers," Matuszewski said. Hospital grafts now make up 89% of BioStem's sales after Medicare pricing changes shrank its doctor-office business, which fell another 27.3% from the second quarter to $0.8 million.
Reported hospital revenue edged up 1.5%, from $6.7 million in the second quarter to $6.8 million in the third. Because the third quarter has 92 days against 91 in the second, hospital sales per day grew 0.2% by our math, staying near $74,000 a day for a third straight quarter. More customers bought multiple products, but average spend per customer did not lift the daily run rate.
What to watch: fourth-quarter hospital revenue in the full-year report. Moving above $7.5 million would show the expanded sales force is finally lifting daily volume.
Overhead and Contract Pricing Widened the Loss
Until BioStem moves manufacturing of Neox and Clarix to its own Florida plant in the first half of 2027, it buys those grafts from BioTissue. In the third quarter, the cost of making the products rose by 5.1 percentage points of revenue from the second quarter, pulling gross margin down from 61.3% to 56.2% "following the expiration of the initial discounted pricing".
At the same time, general and administrative overhead jumped from 82.2% of revenue to 98.6% (+16.4 percentage points), driven by stock-listing fees, financing costs, payroll taxes on stock awards, and the $1.0 million payment extension fee. Total operating expenses reached $14.1 million, or more than triple the $4.3 million of gross profit. Even excluding one-offs, EBITDA loss widened to $6.4 million from $4.6 million in the second quarter.
What to watch: fourth-quarter gross margin and administrative costs. They will show where unit profitability settles on full-price BioTissue supply before the 2027 factory transfer.
Risks this quarter didn't answer
Four standing concerns from the second quarter could not be checked from the third-quarter press release alone.
- Direct sales force size: management previously targeted 40 direct reps by year-end (up from 30 in Q2), and the Q3 call or 10-Q must confirm hiring progress.
- Anti-dilution ratchet: the May stock sale at $3.35 per share carried a price-reset clause, and the 10-Q footnotes will show whether the September financing triggered extra share issuance.
- Going-concern warning: the 10-Q liquidity footnote will confirm that substantial doubt about continuing as a going concern remains in place.
- Voting control: 300 super-voting Series A-1 preferred shares remain outstanding on the balance sheet, leaving voting control concentrated.
👓 Other Themes
Management Plans $10–12 Million in Cost Cuts
To address its cash burn, BioStem is finalizing a cost-cutting plan "expected to reduce annualized cash operating expenses by approximately $10 to $12 million compared with the current run rate", with the full savings starting in the first quarter of 2027. Cash operating expenses in the third quarter were about $11.3 million (excluding $2.1 million of stock compensation and $0.7 million of depreciation), so a $2.5 million to $3.0 million quarterly cut would trim roughly a quarter of cash overhead.
💲 Other KPIs
Inventory climbed 36.9% from the second quarter and has more than doubled from $2.88 million at the end of 2025, even as quarterly sales slipped 3.3%. Stocking up on hospital grafts tied up cash during the quarter, contributing to the jump in operating cash burn.
Unpaid bills and accrued expenses rose 10.6% from the second quarter and are up 135.6% since December 2025. Along with the unpaid $10.0 million BioTissue obligation, total current liabilities reached $22.17 million against $16.13 million in current assets.
BioStem issued 840,023 common shares during the third quarter (+4.7% from June), driven by the $3.0 million private placement on September 30 and stock award vesting. The September financing also created a new $3.08 million long-term warrant liability on the balance sheet.
🔮 Guidance
Raised. Management lifted the bottom of its full-year sales plan by $2.0 million, putting the middle of the range at $28.5 million. With $21.7 million already booked through September, the outlook leaves $6.3 million to $7.3 million for the fourth quarter by our math ($6.8 million at the middle, down 10.7% from Q3). It is the second straight quarter BioStem has raised the bottom of the range while keeping the $29.0 million ceiling.
❓ Key Questions
What are the terms of the BioTissue payment restructuring?
The $10.0 million Clearance Payment remained unpaid past its September 15 extended deadline, and BioStem already booked $1.0 million in extension fees in Q3 while ending September with $1.0 million in cash.
At what price was the $3 million September placement sold?
The May 2026 private placement at $3.35 per share included a nine-month anti-dilution price reset; if the September shares were priced below $3.35, earlier investors receive extra shares.
Where will the $10–12 million in cost cuts come from?
Cutting $2.5 million to $3.0 million per quarter starting in Q1 2027 represents roughly a quarter of current cash overhead, and investors need to know whether sales reps are affected.
Why did hospital revenue per day stay flat at $74,000?
Customers buying two or more product lines grew 14% from Q2, yet total hospital revenue rose only $0.1 million across one extra calendar day.